Bicocca Open Archive

Logo unimib boa
CAIROLI, ROBERTO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
AS - Asia 16.056
NA - Nord America 8.168
EU - Europa 6.426
SA - Sud America 2.121
AF - Africa 317
OC - Oceania 28
Continente sconosciuto - Info sul continente non disponibili 2
Totale 33.118
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 7.855
SG - Singapore 5.827
CN - Cina 3.241
HK - Hong Kong 2.879
RU - Federazione Russa 1.888
IT - Italia 1.761
BR - Brasile 1.673
VN - Vietnam 1.563
IE - Irlanda 899
KR - Corea 761
FR - Francia 375
DE - Germania 346
IN - India 328
BD - Bangladesh 305
ID - Indonesia 247
GB - Regno Unito 239
SE - Svezia 200
FI - Finlandia 172
AR - Argentina 164
IQ - Iraq 148
CA - Canada 146
TR - Turchia 116
NL - Olanda 109
MX - Messico 104
PK - Pakistan 101
ZA - Sudafrica 99
AT - Austria 84
EC - Ecuador 83
UA - Ucraina 79
PH - Filippine 73
ES - Italia 71
SA - Arabia Saudita 71
JP - Giappone 60
UZ - Uzbekistan 51
CO - Colombia 50
VE - Venezuela 48
MA - Marocco 45
TN - Tunisia 36
MY - Malesia 32
CL - Cile 31
EG - Egitto 31
CH - Svizzera 30
JO - Giordania 30
KE - Kenya 30
PL - Polonia 30
AU - Australia 25
PE - Perù 24
PY - Paraguay 23
AZ - Azerbaigian 20
ET - Etiopia 20
KZ - Kazakistan 19
NP - Nepal 19
LB - Libano 18
JM - Giamaica 17
TW - Taiwan 16
AE - Emirati Arabi Uniti 15
DZ - Algeria 15
TH - Thailandia 15
BE - Belgio 14
IR - Iran 14
OM - Oman 14
AL - Albania 13
LT - Lituania 13
IL - Israele 12
CZ - Repubblica Ceca 11
DO - Repubblica Dominicana 11
BO - Bolivia 10
DK - Danimarca 10
GE - Georgia 10
GR - Grecia 10
PS - Palestinian Territory 10
HR - Croazia 9
HU - Ungheria 9
PT - Portogallo 9
UY - Uruguay 9
AO - Angola 8
RO - Romania 8
BH - Bahrain 7
CR - Costa Rica 7
LY - Libia 7
TT - Trinidad e Tobago 7
BG - Bulgaria 6
NO - Norvegia 6
PA - Panama 6
SY - Repubblica araba siriana 6
KW - Kuwait 5
RS - Serbia 5
SN - Senegal 5
BY - Bielorussia 4
GT - Guatemala 4
HN - Honduras 4
KG - Kirghizistan 4
NI - Nicaragua 4
QA - Qatar 4
BA - Bosnia-Erzegovina 3
GY - Guiana 3
NG - Nigeria 3
UG - Uganda 3
AM - Armenia 2
BN - Brunei Darussalam 2
Totale 33.068
Salva come PNG Salva come JPEG
Città #
Singapore 3.219
Hong Kong 2.863
Hefei 1.391
San Jose 1.245
Dublin 848
Ashburn 749
Seoul 745
New York 497
Ho Chi Minh City 480
The Dalles 455
Santa Clara 446
Chicago 422
Hanoi 391
Milan 370
Los Angeles 297
Lauterbourg 281
Dallas 221
Beijing 197
Buffalo 195
Moscow 195
Jakarta 183
São Paulo 167
Council Bluffs 163
Boardman 153
Ann Arbor 126
Helsinki 119
Frankfurt am Main 116
Nuremberg 112
Turin 97
Rome 92
Shanghai 75
Seattle 70
Haiphong 67
Toronto 65
Da Nang 59
Baghdad 56
Rio de Janeiro 51
London 47
Fairfield 46
Lahore 46
Desio 43
Salt Lake City 43
Chandler 42
Tashkent 41
Orem 40
Amsterdam 39
Houston 38
Washington 37
Johannesburg 36
Munich 36
Tampa 36
Tokyo 36
Vienna 35
Montreal 34
Belo Horizonte 33
Biên Hòa 33
Mumbai 33
Dhaka 32
Phoenix 32
Guangzhou 31
Porto Alegre 30
Amman 29
Atlanta 29
Chennai 29
Curitiba 29
Lappeenranta 29
Brasília 28
Naples 27
Wilmington 27
Ha Long 26
Quito 26
Riyadh 26
Istanbul 25
New Delhi 25
Jeddah 24
Nairobi 24
Bologna 23
Brooklyn 23
Miami 23
Ankara 22
Boston 22
Can Tho 22
Guayaquil 22
Jacksonville 22
San Francisco 22
Warsaw 22
Hải Dương 21
Salvador 21
Caracas 20
Kent 20
Mexico City 20
Princeton 20
Changsha 19
Delhi 19
Hyderabad 19
Madrid 19
Paris 19
Redondo Beach 19
Addis Ababa 18
Campinas 18
Totale 19.075
Salva come PNG Salva come JPEG
Nome #
Mutational Landscape of Bone Marrow CD19 and CD138 Cells in Waldenström Macroglobulinemia (WM) and IgM Monoclonal Gammopathy of Undetermined Significance (IgM MGUS) 471
Assessing eligibility for treatment in acute myeloid leukemia in 2023 372
AVALON: The Italian cohort study on real-life efficacy of hypomethylating agents plus venetoclax in newly diagnosed or relapsed/refractory patients with acute myeloid leukemia 343
The role of quantitative polymerase chain reaction in the management of follicular lymphoma patients 268
Lymphoma’s last therapeutic option: Freeze it! 265
Anti-CD38 monoclonal antibody impairs CD34+ mobilization and affects clonogenic potential in multiple myeloma patients 260
Cerebral Infectious Opportunistic Lesions in a Patient with Acute Myeloid Leukaemia: The Challenge of Diagnosis and Clinical Management 256
Advances in the understanding of molecular genetics and therapy ofRichter transformation in chronic lymphocytic leukemia 247
Communicating the diagnosis of a hematological neoplastic disease to patients’ minor children: a multicenter prospective study 237
Clinical characteristics and risk factors associated with COVID-19 severity in patients with haematological malignancies in Italy: a retrospective, multicentre, cohort study 234
RNA hyperediting and alternative splicing of hematopoietic cell phosphatase (PTPN6) gene in acute myeloid leukemia 230
Impact of serial echocardiography in the management of primary cardiac lymphoma 227
Efficacy of Midostaurin Combined With Intensive Chemotherapy in Core Binding Factor Leukemia: A Phase II Clinical Trial 208
Tixagevimab/Cilgavimab Pre-exposure Prophylaxis in Patients with Lymphoproliferative Disorders on BTKi 198
Gilteritinib as Post-Transplant Maintenance for Acute Myeloid Leukemia With Internal Tandem Duplication Mutation of FLT3 196
KIT activating mutations: Incidence in adult and pediatric acute myeloid leukemia, and identification of an internal tandem duplication 193
Optimal Duration of CPX-351 Treatment and Best Timing for Consolidation with Allogeneic Stem Cell Transplantation: Evidence from a Large Real-World Italian Study 190
A phase I/IIa clinical trial of autologous hematopoietic stem cell transplantation in amyotrophic lateral sclerosis 187
Effectiveness and Tolerability of Dual Antiviral Therapy in Immunosuppressed Patients with Protracted SARS-CoV-2 Infection 182
Pirtobrutinib is an Effective Salvage Treatment After Ibrutinib in Bing–Neel Syndrome 177
Fasting and Diet: Overview in Chronic Lymphocytic Leukemia 175
Atezolizumab, venetoclax, and obinutuzumab combination in Richter transformation diffuse large B-cell lymphoma (MOLTO): a multicentre, single-arm, phase 2 trial 174
Adapting the Fitness Criteria for Non-Intensive Treatments in Older Patients with Acute Myeloid Leukemia to the Use of Venetoclax-Hypomethylating Agents Combination.—Practical Considerations from the Real-Life Experience of the Hematologists of the Rete Ematologica Lombarda 173
COVID-19 elicits an impaired antibody response against SARS-CoV-2 in patients with haematological malignancies 170
Long-term survival can be achieved in a significant fraction of older patients with core-binding factor acute myeloid leukemia treated with intensive chemotherapy 168
Impaired survival of patients with non donor-specific anti-HLA antibodies before HLA-mismatched allogeneic stem cell transplantation 165
Gilteritinib in FLT3-mutated acute myeloid leukemia: A real-world Italian experience 163
Current Treatment Options and the Role of Functional Status Assessment in Classical Hodgkin Lymphoma in Older Adults: A Review 162
Exploring the administrative burden faced by hematologists: a comprehensive study in Italy 161
Real World Outcome of Unfit Patients with Acute Myeloid Leukemia Treated with the Combination Venetoclax Plus Hypomethylating Agents in the Gimema AML2320 Observational Trial 161
Next Generation BTK Inhibitors in CLL: Evolving Challenges and New Opportunities 158
Sabatolimab plus hypomethylating agents in previously untreated patients with higher-risk myelodysplastic syndromes (STIMULUS-MDS1): a randomised, double-blind, placebo-controlled, phase 2 trial 154
Coexisting conditions and concomitant medications do not affect venetoclax management and survival in chronic lymphocytic leukemia 153
A GIMEMA survey on therapeutic use and response rates of FLT3 inhibitors in acute myeloid leukemia: Insights from Italian real‐world practice 151
Should Patients with Waldenström Macroglobulinemia Receive a BTK Inhibitor as Frontline Therapy? 149
Transcriptomic Signature of a Patient with Chronic Lymphocytic Leukemia Exhibiting Profound Fluctuations in the Lymphocytosis during Nutrition and Prolonged Fasting Periods 144
"Efficient Strategies for the Reuse of Surgical and FFP2/ KN95 Face Masks during the COVID-19 Pandemic: Home-Made and Ecological Choices for the Community" 143
Use of Sorafenib in FLT3-Mutant Myeloid Sarcoma: A Case Report 140
In vivo differentiation of mast cells from acute myeloid leukemia blasts carrying a novel activating ligand-independent C-kit mutation 139
Bone Marrow CD34+/lin− Cells of Patients with Chronic-Phase Chronic Myeloid Leukemia (CP-CML) After 12 Months of Nilotinib Treatment Exhibit a Different Gene Expression Signature Compared to the Diagnosis and the Corresponding Cells from Healthy Subjects 138
Myeloma’s multiple morphologies 137
A prognostic model for patients with lymphoma and COVID-19: a multicentre cohort study 137
DCEP (dexamethasone, cyclophosphamide, etoposide, and cisplatin) is an effective regimen for peripheral blood stem cell collection in multiple myeloma 135
Mutational Landscape of Bone Marrow CD19 and CD138 Cells in Waldenström Macroglobulinemia (WM) and IgM Monoclonal Gammopathy of Undetermined Significance (IgM MGUS) 134
Cytomegalovirus and Epstein-Barr Virus DNA Kinetics in Whole Blood and Plasma of Allogeneic Hematopoietic Stem Cell Transplantation Recipients 134
Intrahospital COVID-19 infection outbreak management: Keep calm and carry on 132
Results of MOLTO, a multicenter, open label, phase II clinical trial evaluating venetoclax, atezolizumab and obinutuzumab combination in Richter syndrome 129
Hypoplasia of the Spleen: Rare and Puzzling 129
IN ADULT ACUTE MYELOID LEUKEMIA (AML) PERIPHERAL BLOOD MEASURABLE RESIDUAL DISEASE (MRD) BY FLOW CYTOMETRY (FC) IS FEASIBLE AND IS PROGNOSTICALLY RELEVANT 128
Cost-effectiveness analysis of gemtuzumab ozogamicin for the treatment of de novo CD33-positive Acute Myeloid Leukaemia (AML) in Italy 127
A Nine-Gene Expression Signature Distinguished a Patient with Chronic Lymphocytic Leukemia Who Underwent Prolonged Periodic Fasting 124
Risk-adapted MRD-directed therapy for young adults with acute myeloid leukemia: 6-year update of the GIMEMA AML1310 trial 124
Dual antiviral therapy in haematological patients with protracted SARS-CoV-2 infection 124
Saccharomyces cerevisiae fungemia with granulomas in the bone marrow in a patient undergoing BMT 123
Plasma cell-directed therapy and anti-HLA antibody production: A successful combination? 123
ELN2017 risk stratification improves outcome prediction when applied to the prospective GIMEMA AML1310 protocol 122
How Age, Comorbidities and Concomitant Medications Influence Ibrutinib Management and Survival in Waldenstrom Macroglobulinemia 122
Occurrence of L1M Elements in Chromosomal Rearrangements Associated to Chronic Myeloid Leukemia (CML): Insights from Patient-Specific Breakpoints Characterization 122
Cordycepin (3′dA) Induces Cell Death of AC133+ Leukemia Cells via Re-Expression of WIF1 and Down-Modulation of MYC 121
c-kit activating mutations and mast cell proliferation in human leukemia [4] 121
Quantification of 1,3-β-d-glucan by Wako β-glucan assay for rapid exclusion of invasive fungal infections in critical patients: A diagnostic test accuracy study 121
Prognostic significance of CD33, CD34 and CD117 expression on bone marrow blasts of patients with Myelodysplastic syndromes 120
Clinical Impact of Graft Cryopreservation on Allogeneic Stem Cell Transplantation: An Italian, Registry-Based Study on Behalf of the “Gruppo Italiano Per Il Trapianto di Midollo Osseo, Cellule Staminali Emopoietiche e Terapia Cellulare” (GITMO) 119
A sequence of immuno-chemotherapy with Rituximab, mobilization of in vivo purged stem cells, high-dose chemotherapy and autotransplant is an effective and non-toxic treatment for advanced follicular and mantle cell lymphoma 118
Immunochemotherapy with in vivo purging and autotransplant induces long clinical and molecular remission in advanced relapsed and refractory follicular lymphoma 118
VENETOCLAX IN MULTI-RELAPSED MANTLE CELL LYMPHOMA PATIENTS: A REAL-LIFE MULTICENTRIC EXPERIENCE 117
MIS-A: Beware of non-lymphoma 117
Validation of ELN2017 Risk Stratification in a Post-Hoc Analysis of the Prospective Biomarker-Based Gimema AML1310 Protocol 116
A novel start-loss mutation of the SH2B3 gene in a family with myeloproliferative neoplasms 115
Danazol Treatment for Thrombocytopenia in Myelodysplastic Syndromes: Can an "Old-fashioned" Drug be Effective? 115
SOHO State of the Art Updates and Next Questions: What is Fitness in the Era of Targeted Agents? 114
SARS-CoV-2 infection in patients with chronic lymphocytic leukemia: The Italian Hematology Alliance on COVID-19 cohort 113
Identification of hematopoietic progenitor cell donor characteristics predicting successful mobilization: Results of an Italian multicenter study 112
Use of Plerixafor in Poor Mobilizer Patients with Myeloma and Lymphoma: Clonogenic Capacity and Engraftment Data 110
Clinical management of peripherally inserted central catheters compared to conventional central venous catheters in patients with hematological malignancies: A large multicenter study of the REL GROUP (Rete Ematologica Lombarda - Lombardy Hematologic Network, Italy) 110
A study of HLA class I and class II 4-digit allele level in Stevens-Johnson syndrome and toxic epidermal necrolysis 109
Primary Results of Stimulus-MDS1: A Randomized, Double-Blind, Placebo-Controlled Phase II Study of TIM-3 Inhibition with Sabatolimab Added to Hypomethylating Agents (HMAs) in Adult Patients with Higher-Risk Myelodysplastic Syndromes (MDS) 109
Duvelisib for the treatment of chronic lymphocytic leukemia 107
Targeting CD38 to reduce anti-HLA antibody levels: A new and effective option to be integrated into desensitization protocols? 107
A phase I/II study of NMS-03592088, a FLT3, KIT and CSF1R inhibitor, in patients with relapsed or refractory AML or CMML 107
PROGNOSTIC CORRELATION OF CELL-OF-ORIGIN AND MYC, BCL-2 AND BCL-6 STATUS IN HIV-ASSOCIATED DIFFUSE LARGE B-CELL LYMPHOMAS 106
Prognostic impact of C-KIT mutations in Core Binding Factor-Leukemia 105
FZD6 triggers Wnt–signalling driven by WNT10BIVS1 expression and highlights new targets in T-cell acute lymphoblastic leukemia 105
Multidimensional Results and Reflections on CAR-T: The Italian Evidence 105
Response of steroid-refractory chronic graft-versus-host disease to extracorporeal photopheresis correlates with the dose of CD3+ lymphocytes harvested during early treatment cycles 104
GIMEMA AML1310 trial of risk-adapted, MRD-directed therapy for young adults with newly diagnosed acute myeloid leukemia 104
RISK-ADAPTED, MRD-DIRECTED THERAPY FOR YOUNG ADULTS WITH NEWLY DIAGNOSED ACUTE MYELOID LEUKEMIA: RESULTS OF THE AML1310 TRIAL OF THE GIMEMA GROUP 102
PML/RAR alpha transcripts monitored by polymerase chain reaction in acute promyelocytic leukemia during complete remission, relapse and after bone marrow transplantation 102
Nilotinib interferes with cell cycle, ABC transporters and JAK-STAT signaling pathway in CD34+/lin- cells of patients with chronic phase chronic myeloid leukemia after 12 months of treatment 102
Secondary infections worsen the outcome of COVID-19 in patients with hematological malignancies: A report from the ITA-HEMA-COV 102
Philadelphia-like acute lymphoblastic leukemia is associated with minimal residual disease persistence and poor outcome. First report of the minimal residual disease-oriented GIMEMA LAL1913 101
A PHASE II MULTI-CENTER TRIAL OF PENTOSTATIN PLUS CYCLOPHOSPHAMIDE WITH OFATUMUMAB (PCO) IN OLDER PREVIOUSLY UNTREATED CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) PATIENTS 101
Prognostic impact of immunohistochemical p53 expression in bone marrow biopsy in higher risk MDS: A pilot study 101
Clinical characteristics and risk factors for mortality in hematologic patients affected by COVID-19 101
Progressive Down Regulation of JAK-STAT, Cell Cycle, and ABC Transporter Genes in CD34+/Lin- Cells of Chronic-Phase Chronic Myeloid Leukemia (CP-CML) Patients at Diagnosis Vs. 12 Months of Nilotinib Treatment Vs. Healthy Subjects 101
Predicting the probability of Gaucher disease in subjects with splenomegaly and thrombocytopenia 101
IDENTIFICAZIONE DI MIRNA E GENI TARGET NELL’ANALISI TRASCRITTOMICA DELLE CELLULE CD34+/LIN- DI PAZIENTI CON LEUCEMIA MIELOIDE CRONICA IN FASE CRONICA DOPO 12 MESI DI TERAPIA CON NILOTINIB 101
Bortezomib with HIG-dose dexamethasone as first line therapy in patients with multiple myeloma candidates to high-dose therapy 101
"MOLTO", A MULTICENTER, OPEN LABEL, UNCONTROLLED, PHASE II CLINICAL TRIAL ON VENETOCLAX, ATEZOLIZUMAB, OBINUTUZUMAB (AVO) COMBINATION IN RICHTER TRANSFORMATION: SAFETY INTERIM ANALYSIS 100
Alternate use of thrombopoietin receptor agonists in adult primary immune thrombocytopenia patients: A retrospective collaborative survey from Italian hematology centers 100
Totale 14.949
Salva come PNG Salva come JPEG
Categoria #
all - tutte 138.637
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 138.637
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/20218 0 0 0 0 0 0 0 0 0 0 0 8
2021/2022121 6 3 15 7 11 10 2 14 7 8 12 26
2022/20231.417 27 57 11 13 9 26 0 151 58 921 64 80
2023/20243.794 57 115 139 106 515 840 653 200 657 104 76 332
2024/20259.731 545 1.184 457 439 783 295 687 221 844 1.048 1.035 2.193
2025/202618.733 2.037 2.311 1.568 2.487 1.507 934 2.639 904 1.528 1.438 774 606
Totale 34.147